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Aim: to study the activity of antioxidant enzymes and to evaluate an intensity of prooxidant processes in sarcoma 37 (S37) cells 
during tumor development and under influence of sodium dichloroacetate (SDA). Methods: Activity of total superoxide dismutase 
(SOD), SOD isoforms, catalase (Cat), glutathione peroxidase (GP), and glutathione reductase (GR), as well as content of reduced 
glutathione (GSH) and lipid peroxidation (LP) secondary byproducts were determined in S37 homogenated tissues of untreated 
mice and animals treated with SDA at daily dose of 86 mg/kg. Results: SDA treatment of S37-bearing mice resulted in the reduced 
activities of total SOD, SOD isoforms (especially Mn-SOD), Cat, GP and significantly decreased GSH content on the background 
of LP intensification in tumor tissue. Conclusion: The observed changes of oxidative homeostasis in S37-bearing animals treated 
with SDA could be considered as an element of antitumor action of SDA. 
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Tumor growth is characterized by the disturbances 
in metabolic microenvironment associated with the ac-
cumulation of reactive oxygen species (ROS) that provide 
the modification of intracellular signaling pathways in-
volved in regulation of cell proliferation, differentiation, 
cellular death (apoptosis, autophagy) and neoangiogen-
esis, as well as disturbancy in macromolecules and bio-
logical membranes [1, 2]. The primary generation of sub-
stantial amounts of ROS in cells (including these in malig-
nant neoplasms) is associated with electron transfer 
by respiratory complexes of inner mitochondrial mem-
brane [2]. The deficiency of respiratory chain components 
observed in tumor cells creates the conditions for electron 
leakage outwards the complexes and subsequent free 
radicals formation [3].
The intensity of prooxidant processes is found 
to be controlled by antioxidant defense system that com-
prises enzymatic and non-enzymatic components. The 
ability of antioxidant system to neutralize ROS is accompa-
nied with involvement of some components of this system 
within the set of signal transduction pathways associated 
with cell death and division [4]. The special role is assigned 
to the antioxidant enzymes localized in mitochondria since 
they are the primary scavengers of ROS generated dur-
ing electron flow in respiratory chain and are potentially 
capable to prevent from the onset of mitochondrial events 
of apoptosis [1, 4].
The use of substances that cause the death of ma-
lignant cells by inducing the metabolic stress mediated 
by accumulation of the excess amounts of ROS is prom-
ising for the cancer therapy [5]. One of the preparations 
influencing the metabolic processes in mitochondria 
is sodium dichloroacetate (SDA) that selectively inhibits 
pyruvate dehydrogenase kinase activated in tumor cells 
[6]. The possibility of modification of prooxidant-antioxi-
dant homeostasis in tumor cells by the application of SDA 
in vitro is associated with the ability of SDA to affect the 
formation of mitochondrial ROS [6, 7]. 
The aim of the study is to investigate the influence 
of SDA on prooxidant-antioxidant homeostasis of sarcoma 
37 (S37) cells in the dynamics of tumor growth in vivo.
MATERIALS AND METHODS
Experimental design. 112 male Balb/c mice 
2–2.5 months old weighing 20–25 g were used. The 
experimental procedures with animals were conducted 
in accordance to the normative rules on bioethics. 
Sarcoma 37 (S37) cells (2·106 cells per mouse) were 
transplanted into the thigh muscle. S37 cells that give 
rise to highly aggressive and invasive tumors after trans-
plantation [8], were cultivated in RPMI-1640 (Sigma, 
USА) with addition of 10 % fetal bovine serum (Sigma, 
USА), 2 mM L-glutamine and 40 μg/ml gentamicin at 
+37°С in humidified atmosphere with 5% СО2. The viabil-
ity of cells was determined using trypan blue staining.
The animals with transplanted tumors were divided 
into 2 groups: 1 — untreated mice (n = 56); 2 — mice 
that were treated with SDA (intraperitoneal administra-
tion at daily dose of 86 mg/kg from the 2nd day after 
S37 cells transplantation, the total dose of 1548 mg/kg n 
= 56). The SDA dose was selected on the basis of the 
previous results and on the data described in [9]. 
In SDA-treated mice no significant changes of serum 
blood parameters that characterize the state of liver, 
kidney, and lipid metabolism were detected that is in ac-
cordance with the data described in [7, 10] that showed 
the absence of any significant toxicity of 30–100 mg/
kg SDA per day.
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The S37 growth dynamics was registered by evalu-
ation of tumor size in three dimensions on the 6th, 11th, 
14th, 17th , 20th, 24th days after transplantation. The rate 
of tumor growth was evaluated as tumor volume increase 
per time interval. The survival of the animals from the 
both groups was registered. The euthanasia of animals 
under the light ester anaesthetic was carried out on the 
14th, 17th, 20th and 24th day after tumor transplantation. 
Isolation of mitochondria and inner mitochon-
drial membranes. Tumors were washed in physi-
ological saline, the necrosis areas were removed, 
and tumors were homogenized using “BioMix” device 
(Germany) in 20 mM Tris-HCl buffer (pH=7.4, +4°С) 
with 0.32 M sucrose, 2 mM EDTA and 1 mM phenyl-
methylsulfonyl fluoride. After centrifugation (1500 g, 
15 min) the supernatant (S37 homogenate) was further 
centrifuged at 11000 g for 20 min to isolate mitochon-
dria. The sediment of mitochondria was resuspended 
in 30 mM Tris-HCl buffer (pH=7.4, +4°C) containing 
2 mM EDTA and 0.25 M sucrose. 
In order to isolate the inner mitochondrial mem-
branes (IMM) in the form of submitochondrial particles 
mitochondria were frozen with further thawing and 
sedimented by centrifugation at 25000–27000 g dur-
ing 30 min. The purity of the mitochondrial membranes 
was estimated by marker enzyme assays [11]. 
The total protein was determined by bromophenol 
blue assay by Greenberg [12]. 
Lipid peroxidation (LP) assay.  The level 
of thiobarbituric acid reactive substances (TBARS) 
in S37 homogenate and in IMM preparations was de-
termined according to [12]. 
Total catalase and superoxide dismutase activity 
assays. The activity of catalase (Cat) in S37 homog-
enates was evaluated using the method [12] based on the 
measurement of the coloured product of the reaction 
between ammonium molybdate and hydrogen peroxide. 
Cat activity was calculated using the calibration curve 
plotted for catalase purified from human erythrocytes 
(Sigma, USА). The values of Cat activity are represented 
in relative units normalized by protein concentration in the 
sample. One relative unit (r.u.) will decompose 1.0 μmole 
of H2O2 per min at pH 7.0, + 25°C, while the H2O2 concen-
tration falls from 10.3 to 9.2 mM, measured by the rate 
of decrease of absorbance at 240 nm.
The activity of superoxide dismutase (SOD) 
in S37 homogenates was evaluated using the method 
[13]. SOD activity was calculated using the calibra-
tion curve obtained for SOD preparation from bovine 
liver (Sigma, USА). The values of SOD activity are 
represented in relative units normalized by protein 
concentration in the sample. One relative unit (r.u.) 
will reduce nitroblue tetrazolium by 50% at pH 7.8, + 
25°C in a 3.0 ml reaction volume.
The determination of activity of SOD molecular 
forms using non-denaturing PAGE. The preparations 
of tumor homogenates (25 μg of protein) in buffer solu-
tion (25 mM Tris-HCl, 5% glycerol, 0.05% bromophenol 
blue, pH=6.8) were separated in 10% polyacrylamide 
gel in buffer (25 mM Tris, 50 mM glycine, 0.01% SDS) 
at 20 мА, 120 V. The protein molecular weight marker 
(Fermentas, Lithuania) and Сu,Zn-SОD purified from 
human erythrocytes (Sigma, USA) were used as the 
standards. After gel incubation during 40 min at room 
temperature in the dark in reaction mix containing 
2 μM nitroblue tetrazolium in 0.036 mM potassium-
phosphate buffer (pH=7.8) the activity of SOD was 
visualized in photochemical reaction using the solution 
containing 2.8 μM riboflavin and TEMED. Superoxide 
anions generated during the light-induced riboflavin 
transformation reduce nitroblue tetrazolium in the sites 
of SOD activity absence. The activity of SOD molecular 
forms was detected as the achromatic zones in the 
violet-stained gel [14]. Using TotalLab v. 2.01 software 
the relative area of achromatic sites was calculated and 
expressed in relative units of optical density.
Reduced glutathione and glutathione-de-
pendent enzymes assays. The content of reduced 
glutathione (GSH) in S37 homogenates was deter-
mined in accordance with [15] in the reaction with 
5,5’-dithiobis-2-nitrobenzoic acid (DTNBA). The activ-
ity of glutathione peroxidase (GP) in S37 homogenates 
was determined in accordance with procedure based 
on the evaluation of the oxidized glutathione accumu-
lation in the reaction catalyzed by GP [12]. The activity 
of glutathione reductase (GR) in S37 homogenates 
was evaluated by registering the rate of NADPH de-
crease following the GR-catalyzed reduction of oxi-
dized glutathione [12].
All spectrophotometric measurements were 
performed in the 96-well transparent polystyrene 
plates using the multi-mode microplate reader 
“Synergy HT” (BioTek, USA).
Statistical analysis. Statistical analysis of the data 
was performed by means of Origin 8.0 for Windows. 
The significance of statistical differences between 
two groups was evaluated using the Student’s t-test 
(P ≤ 0.05). The data are presented as mean ± SEMs. 
RESULTS
Tumor growth. The kinetics of S37 growth shows 
three-stage pattern (Fig. 1). The initial lag phase 
of S37 growth (I stage) lasts up to 11th day after tu-
mor transplantation. Then tumor volume increases 
by 4 times (P ≤0.05) in the period from the 11th to the 
17th day (II stage) compared to that at the initial lag 
period. Since the 18th day up to the 24th day of the 
experiment (III stage) S37 growth is slower at average 
by 49% (P ≤0.05) in comparison with the preceding 
II stage. These data allow to distinguish exponential 
and stationary phases of S37 growth covering the 
periods from the 11th to the 17th day and from the 18th 
to the 24th day after tumor transplantation respectively.
The administration of SDA to the tumor-bearing 
animals at the daily dose of 86 mg/kg resulted in the 
retardation of S37 growth by 32% (P ≤0.05) in the 
period of II stage and by 53% (P ≤0.05) in the period 
of III stage compared to untreated mice (Fig. 1). 
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Fig. 1. The kinetics of sarcoma 37 growth in untreated Balb/c mice 
(1) and in SDA-treated mice (2). * significant differences (Р ≤ 0.05).
It should be noted that average life span in the 
group of SDA-treated animals was increased by 48% 
(P ≤0.05) in relation to untreated mice (34±6 days 
versus 23±4 days respectively).
The prooxidant processes. During the stage II pe-
riod of S37 growth the content of endogenous secondary 
LP products in S37 cells is relatively stable, while at stage III 
the content of TBARS increases by 37 and 61% respectively, 
compared to that on the 14th day (Fig. 2, а). In S37 cells 
of SDA-treated mice the enhancement of LP is shown: on the 
14th, 17th , 20th and 24th days the TBARS levels in this group 
were higher at average by 92, 62, 64 and 28 % respectively, 
in comparison to the values for untreated mice (Fig. 2, а).
The similar character of TBARS changes was found 
in tumor IMM preparations (Fig. 2, b). The marked ele-
vation of endogenous TBARS level by 142 and 192% 
was observed on the 20th and the 24th days respectively 
as compared with that value on the 14th day of tumor 
growth. In IMM preparations of SDA-treated mice 
the content of LP products on the 20th and the 24th 
days was also increased by 32 and 52% respectively 
compared to the level on the 14th day of S37 growth. 
The administration of SDA to S37-bearing animals 
resulted in the augmentation of LP in tumor IMM. On the 
14th, 17th , 20th and 24th days the level of TBARS in these 
IMM increased significantly by 45, 109, 34 and 28% 
respectively in comparison with IMM from tumors 
of untreated mice (Fig. 2, b).
Fe2+-ascorbate catalyzes nonenzymatic LP in tumor 
IMM. On the 20th and the 24th days of S37 growth TBARS 
levels in S37 IMM were higher by 23 and 65 % respec-
tively as compared to the value on the 14th day. On the 
24th day of S37 growth in IMM from mice treated with 
SDA, 30% increase of LP product content was observed 
as compared with the value on the 14th day (Fig. 2, с). 
For IMM preparations of S37 of SDA-treated mice 
the intensity of LP in the presence of Fe2+ and ascor-
bate is higher as compared with that of untreated mice. 
On the 14th and the 17th days the TBARS content in IMM 
was increased by 76 and 99% and on the 20th and 24th 
days — at average by 38–39% in SDA-treated group 
versus control animals (Fig. 2, с). 
The enzymes of antioxidant defence. The results 
of study of the key antioxidant defence enzymes (SOD 
and Cat) are presented in Table 1. On the 17th, 20th and 
24th day of S37 growth Cat activity is lower by 23, 48 and 
44% in comparison with the 14th day. The reduction of Cat 
activity is also inherent for S37 of SDA-treated mice. Cat 
activity is decreased in these tumors by 46, 51 and 57% 
on the 17th, 20th and 24th days respectively compared 
to the values on the 14th day of S37 growth. On the 14th, 
17th, 20th and 24th days Cat activity in S37 of SDA-treated 
mice was decreased by 39, 58, 42 and 53% respectively 
in comparison with the corresponding values of enzyme 
activity in tumors of untreated animals.
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Fig. 2. The content of TBARS in S37 homogenate (a), in the 
IMM of S37 (b) and the level of the total TBARS detected in the 
presence of Fe2+ and ascorbate in IMM (c) from tumors of un-
treated (1) and SDA-treated mice (2). Significant differences 
(P ≤ 0.05): * — vs. 14-th day, ** — vs. corresponding values for 
SDA-untreated mice. 
On the 17th, 20th and 24th days the activity of to-
tal SOD decreased by 20, 24 and 30% respectively 
in comparison with the 14th day of tumor growth. The 
S37 growth upon SDA influence was also accompanied 
with significant decrease of SOD activity on the 17th 
and 24th days by 20 and 38% respectively compared 
with that on the 14th day (Table 1). SDA administration 
also resulted in significant decrease of total SOD ac-
tivity on the 14th, 17th days by 30% and on the 24th day 
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by 37% respectively as compared with these values 
in untreated mice (Table 1).
Table 1. The activity of catalase (Cat) and superoxide dismutase (SOD) 
in sarcoma 37 during the tumor growth and under influence of SDA
Day of S37   
growth
Cat, r.u./mg SOD, r.u./mg
1 2 1 2
14 66.4±5.4 40.3±3.4** 1.55±0.14 1.09±0.10**
17 51.3±4.1* 21.7±2.1*,** 1.24±0.11* 0.87±0.07*,**
20 34.6±3.1* 19.9±1.5*,** 1.18±0.11* 1.01±0.10
24 37.2±3.2* 17.5±1.4*,** 1.08±0.09* 0.78±0.06*,**
Note: 1 — control animals; 2 — SDA-treated animals; r.u. — relative units. 
Significant differences (P ≤ 0.05): * — vs. 14-th day, ** — vs. correspond-
ing values for SDA-untreated mice.
The activity of SOD in eukaryotic cells is associ-
ated with the existence of enzyme isoforms represented 
by the Cu,Zn-SOD and Mn-SOD which are characterized 
by different structure and localization [13]. The dimeric 
Cu,Zn-SOD (61–64 kDa) and tetrameric Mn-SOD (76–
81 kDa) contribute significantly to the total SOD activity 
in S37 cells. Some part of the observed activity is related 
to dimeric oe monomeric Mn-SOD with molecular weights 
of 40–42 kDa and 20–24 kDa respectively and monomeric 
Cu,Zn-SOD (29–32 kDa) (Table 3). 
The activity of tetrameric Mn-SOD underwent the 
negligible changes during tumor development, but the 
activity of dimeric Cu,Zn-SOD decreased by 46% on the 
24th day of S37 growth as compared with 14th day. The ac-
tivity of Mn-SOD with lower molecular weight decreased 
only on the 24th day of S37 growth (at average by 51% 
compared to the value on the 14th day). At the same time 
the activity of monomeric Cu,Zn-SOD forms and its sepa-
rate subunits (16–18 kDa) decreased at average by 44, 
39 and 52% (P ≤ 0.05) on the 17th, 20th and 24th days 
respectively in comparison with the 14th day (Table 2).
SDA treatment resulted in redistribution of activity be-
tween different SOD forms resulting in the decrease of the 
total SOD activity. In the S37 growth kinetics in SDA-treated 
mice the insignificant changes of tetrameric Mn-SOD 
activity occured with the exception of the 20th day when 
the activity of this molecular form is lower by 48% as com-
pared with that on the 14th day. In this group of animals the 
increase of dimeric Cu,Zn-SOD activity by 29 and 24% was 
observed on the 17th and 20th day (P ≤ 0.05) respectively 
as compared with respective value on the 14th day. 
The dimeric and monomeric Mn-SOD activities de-
creased by 24 and 39% on the 17th and 24th days respec-
tively compared with those on the 14th day. The activity 
of Cu,Zn-SOD with lower molecular weight in S37 of SDA-
treated mice is maintained at the relatively stable level 
except the 20th day when the activity of these forms 
is higher by 26% as compared with that on the 14th day. 
On the 14th day the activity of dimeric Cu,Zn-SOD de-
creased by 35% in comparison with the activity of this mo-
lecular form in untreated mice. On the 17th and the 20th day 
the activity of dimeric Cu,Zn-SOD idecreased by 16 and 
28% and was accompanied with the augmentation of low-
molecular form activity by 41 and 63% respectively. On the 
24th day in the absence of significant changes for dimeric 
Cu,Zn-SOD, the activity of monomeric form and subunits 
of Cu,Zn-SOD increased in tumors of SDA-treated mice 
by 55% (P ≤ 0.05) in comparison with that for untreated 
mice (Table 2). 
Table 2. The relative activity of SOD isoforms in S37 cells during tumor 
development
Day 
of S37 growth 14 17 20 24
Mn-SOD tet-
ramer (76–
81 kDa)
1 250.6±20.1 286.4±24.0 277.1±21.1 281.1±23.1
2 204.1±16.1** 245.1± 20,1 106.2± 
23.1*,**
240.2± 20.1
Cu,Zn-SОD 
dimer (61–
64 kDa)
1 364.8±26.1 366.7± 30.1 409.7± 33.0 196.4±20.1*
2 237.5±20.0** 306.4±22.1*,** 295.4±20.6*,** 189.4±23.1
Mn-SOD 
isoforms 
(40–42 kDa, 
20–24 kDa)
1 212.2±40.5 225.1±35.1 234.2±31.1 105.0±10.2*
2 255.3±30.1 190.1±25.4*,** 253.3±25.1 96.0±10.9*
Cu,Zn-SОD 
isoforms 
(29–32 kDa, 
16–18 kDa)
1 248.1±11.0 140.9±13.1* 153.8±16.1* 120.0±14.1*
2 198.5±20.1 199.2±28.2** 250.2±20.3*,** 186.4±15.1**
Note: 1 — control animals; 2 — SDA-treated animals. Significant differenc-
es (P ≤ 0.05): * — vs. 14-th day, ** — vs. corresponding values for SDA-un-
treated mice. Data are represented in the relative units of optical density.
Besides, the consequence of SDA administration was 
the decrease of total Mn-SOD activity in tumor tissue. 
In this case the activity of tetrameric Mn-SOD is lower 
on the 14th and the 20th days of S37 growth by 19 and 
62% respectively, and the activity of Mn-SOD forms with 
lower molecular weight decreased on the 17th day by 16 % 
as compared with those values in untreated mice.
Glutathione defense system. The reliable changes 
of reduced glutathione level in tumor cells of untreated 
mice were not found during observation period. However, 
in SDA-treated mice GSH content was lower on the 17th, 
20th and 24th days of S37 growth by 41, 35 and 40% respec-
tively as compared with that on the 14th day (Table 3). The 
administration of SDA promoted the exhaustion of GSH 
pool. On the 14th,17th, 20th and 24th days of S37 growth 
the content of GSH decreased by 28, 50, 56 and 55% 
respectively compared with that in untreated mice.
The activity of glutathione-dependent enzymes 
(GP and GR) is rather stable during S37 growth except 
for the 24th day when GR activity decreased by 21% 
compared with that on the 14th day. However, the ad-
ministration of SDA to S37-bearing mice resulted in the 
decrease of GP activity in tumor cells. On the 14th, 17th, 
20th and 24th days of S37 growth GP activity was lower 
by 19, 32, 24 and 27% respectively, as compared with 
untreated mice (Table 3). Alternatively, on the 14th, 20th 
and the 24th days of tumor growth GR activity in tumors 
of SDA-treated mice increased by 22, 40 and 27% 
respectively compared with that for untreated mice.
Table 3. The content of reduced glutathione (GSH) and glutathione-de-
pendent enzymes in sarcoma 37 during tumor development
Da
y 
of
 S
37
 g
ro
wt
h
GSH, nmol /mg
Glutathione peroxi-
dase, μmol GSSG/
mg·min
Glutathione reduc-
tase, μmol NADPH/
mg·min
1 2 1 2 1 2
14 48.1±4.1 34.4±3.1** 97.0±7.4 78.1±5.4** 20.5±2.1 25.0±2.0**
17 40.2±3.4 20.3±2.1*,** 101.7±9.1 69.4±5.3** 21.2±2.0 24.5±2.1
20 50.2±4.4 22.2±2.1*,** 99.1±8.4 72.5±6.4** 18.4±1.4 25.8±2.1**
24 46.1±3.1 20.8±1.7*,** 103.1±10.1 78.4±6.3** 16.1±1.2* 20.4±1.7*,**
Note: 1 — SDA-untreated animals; 2 — SDA-treated animals. Significant dif-
ferences (P ≤ 0.05): * — vs. 14-th day, ** — vs. corresponding values for 
SDA-untreated mice. 
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Hence, sodium dichloroacetate administration results 
in the depletion of GSH pool in S37 in the phase of active 
tumor growth. Concurrently GR activity in S37 cells even 
was increased but GP activity decreased and did not 
change significantly during tumor growth.
DISCUSSION
As we have shown, S37 growth kinetics includes 
3 stages — lag-period, exponential and stationary 
stages. The inhibition of S37 growth by SDA that 
is notable from the 14th day corresponds with the 
data of other authors on the ability of this preparation 
to cause tumor cell death [6, 9, 16]. Taking into ac-
count the involvement of ROS excess in the induction 
of cell death pathways, it is reasonable to expect that 
SDA anticancer effect is mediated by influence of SDA 
on the processes of ROS generation in tumor cells.
The biochemical parameters associated with the 
prooxidant-antioxidant state were studied in S37 on the 
14th, 17th, 20th and 24th days after tumor transplanta-
tion. Although the exponential growth of S37 begins 
on the 11th day the intensity of oxidative processes 
was analysed on the 14th day due to the experimental 
conditions (because tumor volume on the 11th day was 
to small for IMM isolation). Then the parameters were 
detected on the 17th day when the tumor growth passes 
from the exponential to stationary phase and on the 
20th and 24th days when S37 reached the maximal size.
The higher intensity of LP in S37 cells and in tumor 
IMM was shown at stationary phase of S37 growth 
in comparison with exponential phase. The intensification 
of LP in tumors, particularly in mitochondria, results from 
the enhancement of metabolic stress, hypoxic microenvi-
ronment, insufficiency of mitochondria respiratory chain, 
inflammatory process in tumour microenvironment [1, 
2]. These changes are also evidenced by the activation 
of Fe2+-ascorbate — dependent LP in IMM of S37 at the 
same growth stage. The observed LP enhancement 
resulted in modification of structural and dynamical 
properties of mitochondrial membranes [17].
SDA-induced activation of oxidative processes 
in S37 cells, particularly in IMM, is predominantly 
manifested at the exponential stage of S37 growth 
as compared with the values for stationary phase. 
Considering the proposed mechanism of SDA action 
in acceleration of superoxide anion and hydrogen 
peroxide generation in tumor cells in vitro [6] it could 
be assumed that SDA-induced accumulation of ROS 
and products of their transformation may exhibit the 
toxic properties against cellular biomacromolecules 
including protein-lipid complexes, nucleic acids, 
functional groups in the active and regulatory sites 
of enzymes etc. Apparently, it could result in the sub-
sequent death of tumor cells.
Since activation of oxidative processes in cells 
can result from the insufficient antioxidant defense 
systems, we have studied also the functional state 
of the key antioxidant enzymes. The decrease of total 
SOD and Cat activities in S37 cells indicated the defi-
cient level of superoxide anion and hydrogen peroxide 
utilization. The revealed changes are in accordance 
with the data that showed the relationship between 
tumor progression and the changes in activity of these 
enzymes in Lewis lung carcinoma and rat hepatomas 
7288, 5123 and 9618А [18, 19]. 
The activities of total SOD and Cat in S37 cells 
are supressed upon SDA treatment, but they were 
not related to tumor growth dynamics and showed 
no “dose-effect” dependence, so it could be sup-
posed that SOD and Cat activity inhibition is possibly 
related to modification of enzyme functional groups 
by active oxygen radicals. Taking into account also 
the presence of ROS-sensitive sites in the promoter 
regions of genes encoding SOD and Cat, the follow-
ing mechanism of SOD and Cat activity suppression 
could be proposed. High concentrations of ROS block 
the binding of transcription factors to the sites in gene 
promoter regions resulting in subsequent depletion 
of mRNA transcribed from these genes [20]. 
However, the more detailed analysis of the activity 
of SOD separate molecular forms indicated its redis-
tribution between different SOD isoforms in tumor 
growth dynamics in SDA treated mice (in particular, 
decrease of Cu,Zn-SOD activity (predominantly, the 
monomeric form) without significant changes of Mn-
SOD activity). It might be assumed that changes in the 
enzyme structure at the posttranslational level due 
to ROS-driven oxidative modification of functional 
groups in amino acid residues of the enzyme active site 
and/or conformational destabilization of the whole en-
zyme molecule contribute to SOD inhibition in S37 [19]. 
The activity of dimeric Cu,Zn-SOD slightly de-
creased in SDA-treated S37, while the activity of low-
molecular form increased that could be explained 
by the possible loss of structural stability and change 
of conformation properties of enzyme resulting in SOD 
activity inhibition. It should be noted that the increase 
of Cu,Zn-SOD monomer activity could be associated 
with the apparent fragmentation of dimeric Cu,Zn-SOD 
as a result of conformation destabilization in the pres-
ence of free radical oxidants. The negligible decrease 
of Mn-SOD tetramer activity in SDA-treated S37 could 
be caused both by oxidative modification due to in-
crease of the intensity of superoxide anion generation 
in mitochondria and by the inhibition of enzyme by the 
excess of hydrogen peroxide as a product of enzyme-
catalyzed reaction. It was shown [19, 21] that at the 
early stages of formation of hepatomas and Maloney 
sarcoma the mitochondrial Mn-SOD activity did not 
change significantly, but after the appearance of tumor 
node the sharp decrease of this isoform was observed 
in the period of maximal rate of tumor growth. Such 
decrease of Mn-SOD activity enhances the sensitivity 
of mitochondrial membranes to superoxide anion [1].
The demonstrated decrease of GP activity in SDA-
treated S37 indicated the dysfunction in the mecha-
nism of neutralization of lipid hydroperoxides, par-
ticularly in biological membranes. Possibly it might 
be caused by structural rearrangement induced 
by oxidative modification of the enzyme catalytic/al-
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losteric sites or by deficiency of GSH, which content 
also decreases at these conditions. In spite of some 
increase of GR activity in S37 upon SDA treatment, one 
can’t exclude the possible utilization of the reactive 
SH-group of GSH for neutralization of ROS or their 
derivatives [22]. 
Thus, the growth of S37 is accompanied by ROS ac-
cumulation, particularly in mitochondrial membranes, 
concurrently with the functional exhaustion of SOD and 
catalase capacity — superoxide anion and hydrogen 
peroxide scavenger enzymes. The SDA administra-
tion results in the enhancement of lipid peroxidation 
in S37 cells, including mitochondrial membranes, that 
is more apparent on the exponential stage of tumor 
growth. Additional ROS accumulation in S37 cells 
is caused by suppressed activity of SOD, catalase, 
and GP. It could be considered as a result of oxidative 
modification of molecules of these enzymes. In turn, 
the characteristic redistribution of activity between 
the different molecular weight SOD isoforms ischar-
acteristict for S37 cells. The increase of Cu,Zn-SOD 
monomer activity was shown along with depleted func-
tional ability of enzyme dimer that can be related to the 
probable fragmentation of dimeric form due to the loss 
of conformation stability. It should be noted that SDA 
is capable to enhance lipid peroxidation in mitochon-
dria accompanied with Mn-SOD activity decrease. 
Taking into account the available scientific 
evidences it could be assumed that changes of the 
intensity of prooxidant processes and functional ac-
tivity of antioxidant system in sarcoma 37 under SDA 
influence promote the induction of tumor cell death. 
Thus, further investigations of the biochemical and 
molecular mechanisms of anticancer action of SDA 
seem to be reasonable.
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